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Among scientists in the developed world, there has been a recent
resurgence of interest in exotic diseases, with the aim of protect-
ing the global population from emerging infectious disease
threats. The renewed commitment of effort and resources has wel-
come implications for the developing world, whose population
faces the greatest part of these threats. Among the biological
threats considered most serious are the viral hemorrhagic fevers.
Although this term usually brings to mind the deadly outbreaks
of Ebola virus, in reality over 99% of the cases of viral hemorrhag-
ic fever reported worldwide are related instead to dengue hemor-
rhagic fever (DHF) (1).
DHF is caused by the dengue viruses (DENVs), members of the
Flaviviridae family of small enveloped viruses (2). The flaviviruses
carry a single-stranded RNA genome of relatively simple organi-
zation. A single open reading frame in the RNA directs the syn-
thesis of a long polyprotein that is processed by viral and host cell
proteases to produce the ten viral proteins, including three struc-
tural proteins (core [C]; membrane [M], produced as a precursor
protein; and envelope [E]) and seven nonstructural (NS) proteins
(Figure 1). The DENV complex encompasses four closely related
serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. All four
DENV serotypes are transmitted between humans in nature by
mosquitoes of the genus Aedes, principally Aedes aegypti, which is
highly domesticated and has a preference for biting humans.
It has been estimated that over 50 million DENV infections occur
globally each year (3). Most of these infections are clinically inap-
parent. Among symptomatic cases, the majority of subjects experi-
ence uncomplicated dengue fever (DF), an acute febrile illness typ-
ically lasting 3–7 days, accompanied by headache, myalgias, and,
less often, a maculopapular rash. The headache and myalgias may
be quite debilitating, which originated the name “break-bone fever”
that was recorded prior to the 1900s (4). Laboratory findings in
patients with DF include leukopenia thrombocytopenia, and mild
elevations in serum hepatic transaminases (5). Fatigue may be pro-
longed for months after resolution of fever, but patients eventual-
ly recover without sequelae. None of these features is sufficiently
specific for accurate clinical diagnosis of DF. Laboratory support
for detection of IgM antibody or virus (by RT-PCR or virus isola-
tion) is therefore important for recognition of outbreaks.
DHF represents the severe clinical manifestation of DENV infec-
tion, which occurs in no more than 3% of infected individuals (6).
Fever, headache, and myalgias are prominent symptoms in DHF, as
they are in DF. DHF is distinguished from DF on clinical grounds,
with the three primary criteria being the occurrence of a vascular
permeability defect resulting in plasma leakage; multifactorial
hemostatic abnormalities, including marked thrombocytopenia;
and a bleeding diathesis (7). Plasma leakage is evidenced by hemo-
concentration and/or effusions in the pleural or peritoneal spaces,
which usually occur after 3–5 days of fever, near the time of defer-
vescence. When severe, the plasma leakage leads to hypotension and
circulatory collapse, and this is the most important concern for
triage and therapy. Thrombocytopenia is quite severe in DHF, with
a platelet count of less than 100,000 cells/mm3 required to fulfill the
case definition. The nadir of the platelet count is typically coinci-
dent with plasma leakage, and severe thrombocytopenia also occurs
in a significant percentage of patients with DF; nevertheless, the
decline in platelet count typically precedes plasma leakage, and this
finding has been useful in deciding whether to hospitalize patients
suspected to have DHF (8). Bleeding manifestations, for example,
from the gastrointestinal tract, can be severe in patients with DHF
but are not usually severe enough to require transfusion and are
rarely the principal cause of hypotension. Despite the use of the
term “hemorrhagic fever,” many patients with DHF have minor
hemorrhagic manifestations; often the occurrence of petechiae
elicited by inflation of a blood pressure cuff on the arm for 5 min-
utes (the “tourniquet test”) is the only clinical sign.
The emergence of DHF as a global infectious disease threat is
striking in its persistence and magnitude. Southeast Asia and the
western Pacific region, where DHF was first recognized as a clinical
entity, have faced this health problem for almost 50 years. Never-
theless, during each decade the number of DHF cases, the number
of countries affected, and the geographic distribution of DHF have
all increased steadily (3). DHF is, in comparison, a new problem in
the tropical Western hemisphere, but one that has rapidly expand-
ed in scope. Although essentially absent from the area prior to
1981, DHF has during the past decade been seen throughout Latin
America and the Caribbean. It is currently estimated that over 3 bil-
lion individuals live in areas at risk for DHF and that hundreds of
thousands of cases and thousands of deaths due to DHF occur
each year, representing an urgent health problem to be addressed.
Human activities that have led to enhanced mosquito breeding
capacity, increased interaction between mosquitoes and humans,
and increased dispersal of viruses in both mosquito and human
hosts have contributed (and continue to contribute) to the emer-
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not cause chronic infection. Viral replication is effectively con-
trolled after a short (3- to 7-day) period of viremia, and individuals
who have recovered from DENV infection are immune to rechal-
lenge (13). Studies conducted in the 1940s demonstrated that a
DENV strain derived by serial propagation in suckling mouse brain
was attenuated in humans and could elicit protective immunity
against DENV challenge (13).
There are a number of candidate DENV vaccines currently in
development (Table 1) (14). Live attenuated strains of all four
DENV serotypes have been derived by the traditional approach of
serial propagation in primary dog or monkey kidney cells (15–17).
This effort has been slowed by the lack of an animal model or in
vitro markers of attenuation in humans. Improved molecular virol-
ogy techniques and an improved understanding of the genomic
structure of DENV have permitted a more rapid approach based
on engineering of attenuating mutations into infectious cDNA
clones of each of the four DENV serotypes, with the added theo-
retical advantage of a lower possibility of reversion to virulence
(18–20). Another molecular approach being utilized is the creation
of four separate infectious chimeric flaviviruses, each of which con-
tains the pre-M and E genes of one of the four DENV serotypes in
a single “backbone” containing the C and NS proteins of an atten-
uated flavivirus, either the yellow fever vaccine strain or an attenu-
ated DENV strain (21, 22). DNA vaccines consisting of plasmids
expressing one or a few proteins from each DENV serotype are in
an earlier stage of development, as are subunit vaccines based on
purified recombinant DENV proteins (23, 24). Several of these
approaches have demonstrated protective efficacy in animal mod-
els of DENV infection, and a few have shown safety and immuno-
genicity in early phase clinical studies (14, 18, 25, 26).
Two main obstacles have delayed further clinical development of
these candidate vaccines. First, an effective vaccine needs to prevent
infection with all four DENV serotypes. Natural DENV infection
induces long-lasting protective immunity only to the same serotype
and only short-term (months) protection from infection with other
serotypes (13). Although live attenuated and recombinant vaccines
to all four DENV serotypes have been developed, incorporation of
these into a tetravalent formulation that retains the immunogenic-
ity of all four components has proven difficult, requiring the use of
more complicated, multiple-dose immunization regimens (25).
The second and more significant obstacle is the current inability
to predict whether candidate DENV vaccines will be at all effective
in preventing DHF. DHF was unrecognized prior to the late 1950s.
Therefore, the experimental challenge studies in humans conduct-
ed during and shortly after World War II did not attempt to test the
efficacy of candidate vaccines against DHF. Subsequent studies of
candidate vaccines have analyzed efficacy only in experimental ani-
gence of DHF, as discussed in several recent reviews (9, 10). Poorly
planned development has been a major factor, especially in urban
centers of the developing world. The attendant inadequate sanita-
tion and potable water supply, leading to an increase in mosquito
breeding places, and the concentration of susceptible human hosts
in close proximity to the mosquitoes also facilitate transmission.
In the Western hemisphere, A. aegypti have also taken advantage of
the lapse in mosquito control efforts that has occurred since the
1970s and have re-established essentially the full geographical
range they commanded prior to the yellow fever eradication efforts
of the mid-twentieth century.
At present, there is no specific therapy available for DHF. Appro-
priate fluid management to correct hypovolemia has been suc-
cessful in reducing the mortality of DHF (7, 11, 12), but access to
medical services remains problematic in many developing coun-
tries. Mosquito control, which is costly and often ineffective,
remains the only method of preventing DHF currently available.
Development of an effective vaccine against DENVs has therefore
been considered a high priority by the WHO.
Background of dengue vaccine development
In principle, an effective vaccine against DENV is highly feasible.
Unlike the situation with HIV and hepatitis C virus, DENV does
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Figure 1
Organization of the flavivirus genome and its resulting proteins and the
location of the major targets of the immune response. The DENV
genome is a single-stranded sense RNA with a single open reading
frame (ORF; top). The ORF is translated as a single polyprotein (mid-
dle) that is cleaved by viral and host proteases to yield the ten viral pro-
teins: the C protein; the M protein, which is synthesized as the larger
precursor protein pre-M (pM); the major E glycoprotein; and seven NS
proteins involved in viral replication among other functions (bottom).The
strength of the antibody and T cell responses to individual viral proteins
is indicated below.
Table 1
Immunological considerations and current status in development of candidate dengue vaccines
Live attenuated Chimeric virus Plasmid DNA Subunit
No. of dengue antigens included All (10) 2 1 to several Usually 1
(10 for viral “backbone” only)
In vivo replication Yes Yes No No
Elicits T and B cell memory Best Best Excellent Fair: Th, B; Poor: CTL
Anticipated durability of immune response Best Best Good Usually poor
Protective in animal models Yes Yes Yes Yes
Status of vaccine development Phase I/II Phase I/II Preclinical Preclinical
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mal models, none of which faithfully reproduce the DHF syndrome
seen in humans. As a result, selection of the most promising DENV
vaccine candidates will necessarily rely on comparing vaccine-
induced immune responses to a profile of protective immunity
developed from observation of natural DENV infections.
Immune responses to DENV
The principal targets of the immune response to DENV are illus-
trated in Figure 1. The E glycoprotein is the principal component
of the external surface of the DENV virion (27) and is a dominant
target of the response consisting of antibodies against DENV. Anti-
bodies against E have been shown to inhibit viral binding to cells
and to neutralize viral infectivity in vitro (28). Passive transfer of
antibodies against E protected mice from DENV challenge (29).
Antibodies against E show variable degrees of cross-reactivity
among the DENV serotypes, although neutralization of infectivity
by antibodies is usually more serotype specific than virion binding
(28). Binding of antibody to virus at non-neutralizing epitopes, or
at concentrations below the neutralization endpoint, can enhance
the uptake of virions into monocytic cell lines and primary human
monocytes in vitro through interaction with cell surface Ig recep-
tors, a phenomenon known as antibody-dependent enhancement
of infection (ADE) (30). These “enhancing” antibodies do not
increase infection of human DCs, which are highly permissive to
DENV infection, however (31, 32).
While not a component of the virion, the NS1 protein is also an
important target of antibodies against DENV. NS1 is expressed on
the surface of infected cells and is also secreted into the circulation
as a soluble multimer (33). Antibodies against NS1 can trigger com-
plement-mediated lysis of DENV-infected cells in vitro and have
been shown to protect mice from DENV challenge (34). A mono-
clonal antibody directed against the pre-M protein has also been
shown to protect mice from DENV challenge (35); however, the
mechanism of this protection and its relevance to natural protec-
tive immunity are uncertain.
As with other viruses, the CD4+ and CD8+ T cell response to
DENV is directed against multiple viral proteins (Figure 1),
although the NS3 protein appears to be particularly immunogenic,
with a preponderance of the T cell epitopes identified (36, 37).
DENV-reactive T cells vary in their ability to recognize different
DENV serotypes, depending upon the degree of homology at a
given epitope. However, cross-reactivity with multiple serotypes is
common, especially at epitopes in the more highly conserved NS
proteins (38, 39). DENV-reactive CD4+ and CD8+ T cells predomi-
nantly produce high levels of IFN-γ as well as TNF-α, TNF-β, and
chemokines including macrophage inhibitory protein-1β upon
interaction with DENV-infected antigen presenting cells, and are
efficient at lysis of DENV-infected cells in vitro (39, 40).
The extent to which these immune responses contribute to the
long-term protective immunity afforded by natural primary DENV
infection has not been fully defined. Symptomatic DENV infections,
including cases of DHF, can occur despite the presence of antibodies
capable of neutralizing in vitro infection of epithelial cell lines (41,
42). Neutralization of infection in monocytic cells (instead of
enhancement of infection) may be more strongly associated with pro-
tection from DHF (41), although this association has been reported
in only one study. There is very little published information on the
association of specific T cell responses with protection. However,
broadly serotype–cross-reactive IFN-γ production in vitro showed a
weak association with mild disease in a small study cohort (43).
Evidence of an immunological basis for DHF
The principal mechanisms by which DENV infection causes DHF
have been a subject of controversy from the time the syndrome was
first recognized. Opposing views have focused on the effect of viral
and host factors on disease severity (44, 45).
Differences in virulence between naturally circulating DENV
strains had been suspected based on differences in clinical profiles
observed during isolated DENV outbreaks in Indonesia and the
Pacific Islands (46, 47). More recently, studies in Peru and Sri
Lanka have provided more convincing data, demonstrating the
association of DHF with specific viral genotypes and not with oth-
ers (48–50). Specific genetic determinants potentially explaining
this association have been mapped to the E gene and to the 5′ and
3′ untranslated regions of the DENV genome (51–53). However, in
the absence of a validated model of virulence in humans, it has not
been possible to verify that these genetic elements are responsible
for virulence or to confirm any proposed mechanism for virulence.
Key seroepidemiological studies by Halstead and colleagues in
Thailand during the 1960s first suggested an association of
increased risk for DHF with a secondary DENV infection; that is,
a new DENV infection in an individual who had previously experi-
enced one or more DENV infections (54, 55). This hypothesis has
since received strong confirmation from the “experiment of
nature” in a large outbreak of DHF associated with DENV-2 in
Cuba (56), as well as several independent prospective cohort stud-
ies in Southeast Asia (57–59). These observations have provided the
basis for exploration of the possibility of a pathologic role for the
immune response to DENV in the development of DHF. Age,
race/ethnicity, nutritional state, and underlying chronic diseases
such as asthma have also been suggested to contribute to DHF risk,
although the data supporting these associations are weaker and the
mechanisms involved are poorly defined.
Antibodies against DENV can affect the course of disease through
multiple mechanisms (Table 2). Passive transfer of antibody against
DENV did increase viremia titers in nonhuman primates in one
study (60), and recent studies have demonstrated a positive corre-
lation between peak viremia titer and disease severity in humans (61,
62), supporting the idea of the potential in vivo importance of ADE.
The occurrence of DHF during primary DENV infection in the first
year of life in children born to DENV-immune mothers, and who
therefore acquire antibody against DENV transplacentally, also sup-
ports the idea of an in vivo role for ADE (63). However, high viremia
titers in older children and adults with primary DENV infections
and in clinically mild secondary DENV infections indicate that
other factors are involved (64, 65). Immune complex formation in
vivo has been detected in association with complement activation
in patients with severe disease (66). Cross-reactivity of antibodies
against E with plasminogen has been associated with bleeding in
acute DENV infection, although not with DHF (67).
Cytokine production and cytolysis by activated T lymphocytes are
additional potential contributors to disease (Table 2). Elevations of
circulating levels of activation markers including soluble TNF
receptors, soluble IL-2 receptors, and soluble CD8 have been shown
to correlate with disease severity (61, 68–71). Similar associations
with disease severity have been shown for the expression of activa-
tion markers on circulating CD8+ T cells (72) and the expansion of
DENV epitope–specific T cell populations (73, 74). Increased pro-
duction of various cytokines, including IFN-γ, TNF-α, IL-10, and
chemokines has also been detected in acute DENV infection (69–71,
75–77). Although elevations in both type 1 and type 2 cytokine lev-
review series
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els are detected in DHF, the timing of their production appears to
be an important factor with earlier induction of type 1 cytokines
being associated with more severe disease (61). Analysis of T cell
responses to DENV prior to secondary DENV infections showed an
association between in vitro TNF-α responses to DENV antigens
and more severe disease during the subsequent infection (43).
Heterologous immunity and the pathogenesis of DHF
Although similar response mechanisms appear to operate in both
protective and pathological immunity to DENV, a principal
immunological consideration is the heterologous nature of sec-
ondary DENV infection. The DENV causing secondary disease is
always of a different serotype than the virus that induced immune
responses during the earlier DENV infection, and therefore the
antibodies and memory T lymphocytes induced by the primary
DENV infection typically encounter antigens that differ (although
some may be the same) in sequence from their original target anti-
gen. The magnitude of these sequence differences is epitope depen-
dent, but all sequence differences have the potential to affect the
quality of the effector response and also modify the immunologi-
cal repertoire. We speculate that the immune response to these het-
erologous sequences has the net effect of altering the balance
between a protective and pathological outcome.
The effect of sequence differences at antibody-binding sites is to
reduce the avidity of the interactions between the pre-existing anti-
bodies and the new DENV serotype. These less avid interactions
have a significant effect on the ability of the antibodies to neutral-
ize virus infectivity. However, there is sufficient binding of antibody
to the virion to trigger ADE. In addition, these low-avidity antibod-
ies increase in titer in preference to new antibodies with high avidi-
ty for the new DENV serotype, because the pre-existing memory B
cells and plasma cells are more rapidly activated than naive B cells.
The pattern of antibody responses in convalescence, therefore, is
influenced heavily by the serotype of the primary DENV infection,
a phenomenon referred to as “original antigenic sin” (78).
The effect of sequence differences at T cell epitopes is more com-
plex, consistent with the wider range of effector functions of T
cells. Variant peptides, or altered peptide ligands, induce different
activation signals in antigen-specific T lymphocytes and thereby
modulate specific effector functions of CD4+ and CD8+ T cells (79,
80). In general, such partial T cell agonists have the greatest effect
on the proliferation responses and less effect on cytotoxicity
responses. Some partial T cell agonists fail to induce cytokine pro-
duction, whereas others induce an altered cytokine response pro-
file. We have observed just such effects in the in vitro responses of
DENV-reactive T cells to peptides of heterologous DENV serotypes
(81). Furthermore, a phenomenon analogous to “original antigenic
sin” would be expected to occur in the T cell response to secondary
DENV infections, in which expansion of the pre-existing lower
avidity memory T cell populations takes precedence over the
expansion of naive T cell populations with higher avidity for the
new DENV serotype. Recent studies of the T cell repertoire after
secondary DENV infection support this view (74).
The potential importance of heterologous immunity in influ-
encing the severity of DENV disease is bolstered by data from an
animal model of sequential virus infections. In this experimental
system, previous infection with one virus (e.g., lymphocytic chori-
omeningitis virus) altered the response to a subsequent vaccinia
virus challenge, altering the hierarchy of epitope-specific T cell
responses and resulting in lower virus titers but greater tissue
Table 2
Postulated pathologic mechanisms of DENV-reactive immune responses in the development of DHF
Mechanism Postulated effect(s) References
Antibodies
Enhancement of infection Increased cellular infection, increased viral burden (45, 60, 84)
Immune complex formation Complement activation (66, 85, 86)
Cross-reactivity to coagulation and endothelial cell proteins Bleeding, endothelial cell dysfunction (67, 87, 88)
T lymphocytes
Proinflammatory cytokine production Increased vascular permeability (61, 68, 69)
Lysis of bystander (uninfected) cells Hepatic injury (40)
Figure 2
Proposed model of heterologous immunity in secondary dengue virus
infections and its implications for the pathogenesis of dengue hemor-
rhagic fever. Primary DENV-2 infection and sequential DENV-1 and
DENV-2 infections are compared for illustration purposes. The naive T
cell repertoire (pale colors) likely contains some cells with higher avid-
ity for DENV-1 than DENV-2 (red; DENV-1 > DENV-2) and other cells
with higher avidity for DENV-2 than DENV-1 (blue; DENV-2 > DENV-1).
During primary infection, T cell populations with higher avidity for the
infecting serotype are preferentially expanded and enter the memory
pool (shown as darker colors). When DENV-2 infection follows DENV-1
infection, the memory T cell populations with higher avidity for the ear-
lier infection expand more rapidly than do naive T cell populations.
Because these DENV-1–specific memory T cells have lower avidity for
DENV-2, viral clearance mechanisms are suboptimal, whereas proin-
flammatory responses contribute to disease.
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inflammation (82, 83). A model for the effect of heterologous
immunity in the pathogenesis of DHF is shown in Figure 2. We
postulate that the low-avidity T cells that dominate the response
to secondary DENV infections are less than optimally efficient at
elimination of DENV-infected cells and that the pattern of
cytokine production is altered such that proinflammatory cytokine
production (e.g., TNF-α) is enhanced and antiviral cytokine pro-
duction (e.g., IFN-γ) is reduced. These effects could combine to
induce the plasma leakage symptomatic of DHF.
Responding to the challenge
To maximize protection and minimize pathologic heterologous
immunity and achieve long-lasting immune responses, an optimal
vaccine to prevent DENV infections including DHF should induce
high-avidity antibodies and T lymphocytes against all four DENV
serotypes. The theoretical advantages of live attenuated virus vac-
cines or plasmid DNA vaccines (Table 1) have placed them on a
faster track toward clinical development. Tetravalent attenuated
vaccines have been developed, but researchers have encountered
problems in finding a formulation that balances the immuno-
genicity of all four viruses (25). Recombinant chimeric flavivirus
vaccines show promise in induction of antibodies against E (21), but
it will be important to determine whether the common epitopes in
the NS proteins of the viral “backbone” will induce optimal T cell
responses. Some findings suggest that individuals with mild and
severe disease target different epitopes in their T cell response to
DENV (73). Nucleotide sequences from different DENVs could the-
oretically be introduced into a single vaccine “backbone” to provide
the most favorable targets for a high-avidity, cross-serotype immune
response. Much additional research is needed to identify and char-
acterize protective and pathological immune responses in order to
make an effective DENV vaccine a reality.
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